Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease

J Jean Chen1, David H Salat, H Diana Rosas

  • 1A.A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, USA. jjchen@nmr.mgh.harvard.edu

Neuroimage
|September 28, 2011
PubMed

Insights

Cerebral blood flow (CBF) is reduced in early Huntington's disease (HD), particularly in the cortex. These CBF changes are linked to cognitive deficits, offering new insights into HD.

Area of Science:

  • Neuroscience
  • Neurology
  • Medical Imaging

Background:

  • Cerebral blood flow (CBF) alterations are implicated in neurodegenerative disorders like Huntington's disease (HD).
  • Previous studies suggest CBF reductions in HD, but their extent and relationship with atrophy and symptoms remain unclear.

Purpose of the Study:

  • To investigate regional CBF changes in early-stage HD using non-invasive MRI techniques.
  • To explore the relationship between CBF reductions, regional atrophy, and clinical symptoms in HD patients.

Main Methods:

  • Pulsed arterial-spin labeling MRI was employed to measure regional CBF.
  • High-resolution anatomical MRI was used for assessing regional atrophy.
  • 17 early-stage HD subjects and 41 healthy controls were included.

Main Results:

  • Profound and heterogeneous CBF reductions were observed in the HD cortex, affecting sensorimotor, temporal, and occipital regions.
  • Subcortical CBF was also significantly reduced, comparable to cortical changes.
  • The association between CBF reduction and atrophy was complex and region-dependent.
  • CBF alterations correlated with performance on cognitive tests like the Stroop task.

Conclusions:

  • Early-stage HD is characterized by widespread cortical and subcortical CBF reductions.
  • CBF changes, rather than atrophy alone, may significantly contribute to cognitive impairments in HD.
  • These findings have implications for understanding HD pathogenesis, progression, and therapeutic strategies.

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...